Corient Private Wealth LLC Acquires 2,087 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Corient Private Wealth LLC boosted its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 0.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 239,163 shares of the company’s stock after buying an additional 2,087 shares during the quarter. Corient Private Wealth LLC’s holdings in Ionis Pharmaceuticals were worth $8,361,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC grew its holdings in Ionis Pharmaceuticals by 1.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 21,826 shares of the company’s stock valued at $763,000 after purchasing an additional 373 shares during the period. Swiss National Bank lifted its position in shares of Ionis Pharmaceuticals by 8.8% during the 4th quarter. Swiss National Bank now owns 279,200 shares of the company’s stock valued at $9,761,000 after buying an additional 22,600 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Ionis Pharmaceuticals by 606.8% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,389 shares of the company’s stock worth $4,384,000 after acquiring an additional 107,648 shares during the period. Essential Planning LLC. bought a new position in shares of Ionis Pharmaceuticals during the 4th quarter worth $428,000. Finally, PNC Financial Services Group Inc. increased its holdings in Ionis Pharmaceuticals by 11.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 10,994 shares of the company’s stock worth $384,000 after acquiring an additional 1,101 shares during the last quarter. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Stock Down 1.8 %

Shares of NASDAQ:IONS opened at $32.73 on Friday. The firm has a market capitalization of $5.20 billion, a PE ratio of -10.77 and a beta of 0.28. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. Ionis Pharmaceuticals, Inc. has a 52-week low of $30.23 and a 52-week high of $52.34. The firm has a fifty day moving average of $32.63 and a 200 day moving average of $36.44.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.46. The firm had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company’s revenue was down 30.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.12 EPS. As a group, research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Michael R. Hayden acquired 5,000 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, December 23rd. The shares were purchased at an average cost of $36.22 per share, with a total value of $181,100.00. Following the completion of the purchase, the director now owns 35,219 shares of the company’s stock, valued at $1,275,632.18. This represents a 16.55 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Patrick R. O’neil sold 1,207 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $32.35, for a total value of $39,046.45. Following the completion of the sale, the executive vice president now directly owns 56,245 shares of the company’s stock, valued at approximately $1,819,525.75. This trade represents a 2.10 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 111,956 shares of company stock valued at $3,608,439. 2.71% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have commented on IONS. StockNews.com raised shares of Ionis Pharmaceuticals to a “sell” rating in a report on Tuesday. JPMorgan Chase & Co. dropped their price target on shares of Ionis Pharmaceuticals from $51.00 to $47.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 11th. Citigroup reduced their price objective on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Needham & Company LLC restated a “buy” rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. Finally, William Blair reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $59.56.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.